Pyxis Oncology (PYXS) Share-based Compensation (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Share-based Compensation of -$9.6 million for Q4 2025, down 445.15% year-over-year from $2.8 million in Q4 2024, and down 247.25% quarter-over-quarter from $6.5 million in Q3 2025.
Pyxis Oncology (PYXS) Share-based Compensation (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Share-based Compensation for 6 consecutive years, with -$9.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 445.15% year-over-year to -$9.6 million; the TTM figure through Dec 2025 stood at $6.0 million (down 69.81% YoY), while the FY2025 annual figure was $6.0 million, down 53.65% from the prior year.
- Share-based Compensation retreated to -$9.6 million in Q4 2025 per PYXS's latest filing, from $6.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.0 million in Q1 2025 and bottomed at -$9.6 million in Q4 2025.
- Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.3 million in 2022.
- Annual changes were most pronounced in 2021 — Share-based Compensation jumped 27763.64% — and 2025, when it slumped 445.15%.
- Pyxis Oncology's Share-based Compensation stood at $3.0 million in 2021, then increased by 28.1% to $3.9 million in 2022, then declined by 17.52% to $3.2 million in 2023, then slipped by 13.75% to $2.8 million in 2024, then plunged by 445.15% to -$9.6 million in 2025.
- Business Quant data shows PYXS's Share-based Compensation at -$9.6 million in Q4 2025, $6.5 million in Q3 2025, and $8.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Jun 30, 2026 | 5.80 Mn |
| Dec 31, 2025 | -9.57 Mn |
| Dec 31, 2025 | -9.57 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Jun 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | 8.30 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Mar 31, 2025 | 11.00 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 3.22 Mn |
| Dec 31, 2023 | 3.22 Mn |